Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
13.36
+0.19 (1.44%)
At close: Dec 20, 2024, 4:00 PM
13.45
+0.09 (0.67%)
After-hours: Dec 20, 2024, 4:07 PM EST
Myriad Genetics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Myriad Genetics stock have an average target of 23.92, with a low estimate of 13 and a high estimate of 35. The average target predicts an increase of 79.04% from the current stock price of 13.36.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for MYGN stock from 12 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 4 | 4 | 4 | 4 | 2 |
| Hold | 2 | 3 | 4 | 4 | 4 | 6 |
| Sell | 2 | 2 | 2 | 2 | 2 | 3 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Sell Maintains $15 → $13 | Sell | Maintains | $15 → $13 | -2.69% | Dec 13, 2024 |
| UBS | UBS | Hold Initiates $18 | Hold | Initiates | $18 | +34.73% | Dec 10, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $30 → $21 | Buy → Hold | Downgrades | $30 → $21 | +57.19% | Dec 9, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $32 → $21 | Hold | Maintains | $32 → $21 | +57.19% | Nov 18, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $30 → $24 | Hold | Maintains | $30 → $24 | +79.64% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
857.30M
from 753.20M
Increased by 13.82%
Revenue Next Year
896.65M
from 857.30M
Increased by 4.59%
EPS This Year
0.13
from -3.18
EPS Next Year
0.10
from 0.13
Decreased by -22.95%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 887.3M | 941.8M | 1.0B | ||
| Avg | 857.3M | 896.7M | 977.9M | ||
| Low | 821.0M | 814.8M | 841.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.8% | 9.9% | 16.7% | ||
| Avg | 13.8% | 4.6% | 9.1% | ||
| Low | 9.0% | -5.0% | -6.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.18 | 0.27 | 0.69 | ||
| Avg | 0.13 | 0.10 | 0.37 | ||
| Low | 0.12 | -0.18 | -0.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 103.9% | 571.8% | ||
| Avg | - | -22.9% | 254.9% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.